Coloradans will soon be able to take psychedelic mushrooms in a regulated environment as the state’s natural medicine program ...

Researchers are developing a groundbreaking, non-medication approach to combat insomnia, particularly in military personnel.

ABX-002 is under clinical development by Autobahn Therapeutics and currently in Phase II for Major Depressive Disorder.

Crews from the Tennessee Department of Transportation treated roadways on Sunday morning after winter weather.

Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Shares of Neumora Therapeutics NMRA lost more than 80% on Thursday after reporting the failure of its lead pipeline drug, ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Medically reviewed by Dakari Quimby, PhD Male postpartum depression describes when a new father experiences postpartum ...

Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.